Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 16/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 16/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 0.81 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.81 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.81 |
| ▸ | GSK3B | P49841 | 1/20 | 0.81 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.81 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.81 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.62 |
| ▸ | PAK4 | O96013 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13906194 | 0.90 | CCNA2 (0.81) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL13906188 | 0.89 | CDK2 (0.80) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL2915893 | 0.88 | CDK2 (0.80) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL2916420 | 0.87 | CDK2 (0.77) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL5110745 | 0.84 | CCNA2 (0.72) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL13914858 | 0.82 | CDK2 (0.69) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL2919859 | 0.81 | CDK2 (0.68) | CDK2CCNA2CCNA1NTRK1PAK4 | |
| SCHEMBL2916796 | 0.81 | CDK2 (0.68) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL3485206 | 0.81 | CDK2 (0.67) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL3457234 | 0.80 | CCNA2 (0.73) | CDK2CCNA2CCNA1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266987-B1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-05-17 | — | — | EP | claimed |
| US-8557857-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-10-15 | — | — | US | claimed |
| US-20130017170-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-17 | — | — | US | claimed |
| US-20130012507-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-10 | — | — | US | claimed |
| EP-2266987-A1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | Pfizer Italia S.r.l. (IT) | 2010-12-29 | — | — | EP | claimed |
| US-20090082346-A1 | Substituted Pyrrolo-Pyrazole Derivatives as Kinase Inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-03-26 | — | — | US | claimed |
| WO-2023009833-A9 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-2266987-B1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-05-17 | — | — | EP | disclosed |
| EP-1575954-B1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-08-03 | — | — | EP | disclosed |
| US-8785448-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-22 | — | — | US | disclosed |
| US-8785448-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-22 | — | — | US | disclosed |
| US-20130344031-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-12-26 | — | — | US | disclosed |
| US-8557857-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-10-15 | — | — | US | disclosed |
| US-7407971-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2008-08-05 | — | — | US | disclosed |
| US-7407971-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2008-08-05 | — | — | US | disclosed |
| US-20070004705-A1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-01-04 | — | — | US | disclosed |
| US-20070004705-A1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-01-04 | — | — | US | disclosed |
| US-20070004705-A1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-01-04 | — | — | US | disclosed |
| EP-1575954-A2 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004056827-A2 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004705-A1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | CCNI, CDK1, CDK2 | CDK2 3/4885CCNA2 117/4885CCNA1 41/4885 |
| US-20130344031-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | CCNI, CDK1, CDK2 | CDK2 3/4885CCNA2 117/4885CCNA1 41/4885 |
| US-20130012507-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | CCNI, CDK1, CDK2 | CDK2 3/4885CCNA2 117/4885CCNA1 41/4885 |
| US-20090082346-A1 | Substituted Pyrrolo-Pyrazole Derivatives as Kinase Inhibitors | CCNI, CDK1, CDK2 | CDK2 3/4885CCNA2 117/4885CCNA1 41/4885 |
| US-20130017170-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | CCNI, CDK1, CDK2 | CDK2 3/4885CCNA2 117/4885CCNA1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.